Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1337 entries
Sorted by: Best Match Show Resources per page
Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity.

F1000Research

Koltai T.
PMID: 26097685
F1000Res. 2015 Jan 12;4:9. doi: 10.12688/f1000research.5827.2. eCollection 2015.

OBJECTIVE: To review the mechanisms of anti-cancer activity of nelfinavir and other protease inhibitors (PIs) based on evidences reported in the published literature.METHODS: We extensively reviewed the literature concerning nelfinavir (NFV) as an off target anti-cancer drug and other...

Cite
Koltai T. Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. F1000Res. 2015;4:9doi: 10.12688/f1000research.5827.2.
Koltai, T. (2015). Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. F1000Research, 49. https://doi.org/10.12688/f1000research.5827.2
Koltai, Tomas. "Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity." F1000Research vol. 4 (2015): 9. doi: https://doi.org/10.12688/f1000research.5827.2
Koltai T. Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. F1000Res. 2015 Jan 12;4:9. doi: 10.12688/f1000research.5827.2. eCollection 2015. PMID: 26097685; PMCID: PMC4457118.
Copy Download .nbib Format: NLM
Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study.

The International journal of angiology : official publication of the International College of Angiology, Inc

Sule AA, Pandit N, Handa P, Chadachan V, Tan E, Sum FN, Joyce EH, Chin TJ.
PMID: 24436591
Int J Angiol. 2013 Jun;22(2):95-100. doi: 10.1055/s-0033-1333866.

Introduction Human immunodeficiency virus (HIV) patients are at risk of developing thrombosis than general population. There are several intersecting mechanisms associated with HIV infection and antiviral therapy that are emerging, which may lead to vasculopathy and hypercoagulability in these...

Cite
Sule AA, Pandit N, Handa P, et al. Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study. Int J Angiol. 2013;22(2):95-100doi: 10.1055/s-0033-1333866.
Sule, A. A., Pandit, N., Handa, P., Chadachan, V., Tan, E., Sum, F. N., Joyce, E. H., & Chin, T. J. (2013). Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study. The International journal of angiology : official publication of the International College of Angiology, Inc, 22(2), 95-100. https://doi.org/10.1055/s-0033-1333866
Sule, Ashish Anil, et al. "Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study." The International journal of angiology : official publication of the International College of Angiology, Inc vol. 22,2 (2013): 95-100. doi: https://doi.org/10.1055/s-0033-1333866
Sule AA, Pandit N, Handa P, Chadachan V, Tan E, Sum FN, Joyce EH, Chin TJ. Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study. Int J Angiol. 2013 Jun;22(2):95-100. doi: 10.1055/s-0033-1333866. PMID: 24436591; PMCID: PMC3709953.
Copy Download .nbib Format: NLM
Studies of inhibitory mechanisms of propeptide-like cysteine protease inhibitors.

Enzyme research

Nga BT, Takeshita Y, Yamamoto M, Yamamoto Y.
PMID: 25045530
Enzyme Res. 2014;2014:848937. doi: 10.1155/2014/848937. Epub 2014 Jun 19.

Mouse cytotoxic T-lymphocyte antigen-2α (CTLA-2α), Drosophila CTLA-2-like protein (crammer), and Bombyx cysteine protease inhibitor (BCPI) belong to a novel family of cysteine protease inhibitors (I29). Their inhibitory mechanisms were studied comparatively. CTLA-2α contains a cysteine residue (C75), which is...

Cite
Nga BT, Takeshita Y, Yamamoto M, et al. Studies of inhibitory mechanisms of propeptide-like cysteine protease inhibitors. Enzyme Res. 2014;2014:848937doi: 10.1155/2014/848937.
Nga, B. T., Takeshita, Y., Yamamoto, M., & Yamamoto, Y. (2014). Studies of inhibitory mechanisms of propeptide-like cysteine protease inhibitors. Enzyme research, 2014848937. https://doi.org/10.1155/2014/848937
Nga, Bui T T, et al. "Studies of inhibitory mechanisms of propeptide-like cysteine protease inhibitors." Enzyme research vol. 2014 (2014): 848937. doi: https://doi.org/10.1155/2014/848937
Nga BT, Takeshita Y, Yamamoto M, Yamamoto Y. Studies of inhibitory mechanisms of propeptide-like cysteine protease inhibitors. Enzyme Res. 2014;2014:848937. doi: 10.1155/2014/848937. Epub 2014 Jun 19. PMID: 25045530; PMCID: PMC4089206.
Copy Download .nbib Format: NLM
Hepatitis C in Argentina: epidemiology and treatment.

Hepatic medicine : evidence and research

Gaite LA, Marciano S, Galdame OA, Gadano AC.
PMID: 24966701
Hepat Med. 2014 May 27;6:35-43. doi: 10.2147/HMER.S57774. eCollection 2014.

Hepatitis C is the leading cause of chronic hepatitis, cirrhosis, and liver cancer in Argentina, where from 1.5% to 2.5% of adults are infected. Most of the infections were acquired 30-50 years ago. It is estimated that more than...

Cite
Gaite LA, Marciano S, Galdame OA, et al. Hepatitis C in Argentina: epidemiology and treatment. Hepat Med. 2014;6:35-43doi: 10.2147/HMER.S57774.
Gaite, L. A., Marciano, S., Galdame, O. A., & Gadano, A. C. (2014). Hepatitis C in Argentina: epidemiology and treatment. Hepatic medicine : evidence and research, 635-43. https://doi.org/10.2147/HMER.S57774
Gaite, Luis Alejandro, et al. "Hepatitis C in Argentina: epidemiology and treatment." Hepatic medicine : evidence and research vol. 6 (2014): 35-43. doi: https://doi.org/10.2147/HMER.S57774
Gaite LA, Marciano S, Galdame OA, Gadano AC. Hepatitis C in Argentina: epidemiology and treatment. Hepat Med. 2014 May 27;6:35-43. doi: 10.2147/HMER.S57774. eCollection 2014. PMID: 24966701; PMCID: PMC4043810.
Copy Download .nbib Format: NLM
Differential transcript profile of inhibitors with potential anti-venom role in the liver of juvenile and adult .

PeerJ

Gomes CM, de Morais-Zani K, Lu S, Buarque DS, Braz GRC, Grego KF, Tanaka AS, Tanaka-Azevedo AM.
PMID: 28462021
PeerJ. 2017 Apr 27;5:e3203. doi: 10.7717/peerj.3203. eCollection 2017.

BACKGROUND: Snakes belonging to the METHODS: In order to identify anti-venom molecules, we construct a cDNA library from the liver of RESULTS: The results revealed a 30-fold increase of gamma-phospholipase ADISCUSSION: The results suggest the up-regulation of different inhibitors...

Cite
Gomes CM, de Morais-Zani K, Lu S, et al. Differential transcript profile of inhibitors with potential anti-venom role in the liver of juvenile and adult . PeerJ. 2017;5:e3203doi: 10.7717/peerj.3203.
Gomes, C. M., de Morais-Zani, K., Lu, S., Buarque, D. S., Braz, G. R. C., Grego, K. F., Tanaka, A. S., & Tanaka-Azevedo, A. M. (2017). Differential transcript profile of inhibitors with potential anti-venom role in the liver of juvenile and adult . PeerJ, 5e3203. https://doi.org/10.7717/peerj.3203
Gomes, Cícera Maria, et al. "Differential transcript profile of inhibitors with potential anti-venom role in the liver of juvenile and adult ." PeerJ vol. 5 (2017): e3203. doi: https://doi.org/10.7717/peerj.3203
Gomes CM, de Morais-Zani K, Lu S, Buarque DS, Braz GRC, Grego KF, Tanaka AS, Tanaka-Azevedo AM. Differential transcript profile of inhibitors with potential anti-venom role in the liver of juvenile and adult . PeerJ. 2017 Apr 27;5:e3203. doi: 10.7717/peerj.3203. eCollection 2017. PMID: 28462021; PMCID: PMC5410159.
Copy Download .nbib Format: NLM
AVASCULAR NECROSIS OF THE FEMORAL HEAD IN HIV-INFECTED PATIENTS: PRELIMINARY RESULTS FROM SURGICAL TREATMENT FOR CERAMIC-CERAMIC JOINT REPLACEMENT.

Revista brasileira de ortopedia

Cabrita HA, Santos AL, Gobbi RG, Lima AL, Oliveira PR, Ejnisman L, Gurgel HM, Uip D, Camanho GL.
PMID: 27047876
Rev Bras Ortop. 2015 Nov 04;47(5):626-30. doi: 10.1016/S2255-4971(15)30014-8. eCollection 2012.

OBJECTIVES: To evaluate the initial functional results and early complication rate of ceramic-ceramic total hip replacements among patients living with HIV who presented osteonecrosis of the femoral head.METHOD: Twelve HIV-positive patients with a diagnosis of osteonecrosis of the incongruent...

Cite
Cabrita HA, Santos AL, Gobbi RG, et al. AVASCULAR NECROSIS OF THE FEMORAL HEAD IN HIV-INFECTED PATIENTS: PRELIMINARY RESULTS FROM SURGICAL TREATMENT FOR CERAMIC-CERAMIC JOINT REPLACEMENT. Rev Bras Ortop. 2015;47(5):626-30doi: 10.1016/S2255-4971(15)30014-8.
Cabrita, H. A., Santos, A. L., Gobbi, R. G., Lima, A. L., Oliveira, P. R., Ejnisman, L., Gurgel, H. M., Uip, D., & Camanho, G. L. (2012). AVASCULAR NECROSIS OF THE FEMORAL HEAD IN HIV-INFECTED PATIENTS: PRELIMINARY RESULTS FROM SURGICAL TREATMENT FOR CERAMIC-CERAMIC JOINT REPLACEMENT. Revista brasileira de ortopedia, 47(5), 626-30. https://doi.org/10.1016/S2255-4971(15)30014-8
Cabrita, Henrique Amorim, et al. "AVASCULAR NECROSIS OF THE FEMORAL HEAD IN HIV-INFECTED PATIENTS: PRELIMINARY RESULTS FROM SURGICAL TREATMENT FOR CERAMIC-CERAMIC JOINT REPLACEMENT." Revista brasileira de ortopedia vol. 47,5 (2012): 626-30. doi: https://doi.org/10.1016/S2255-4971(15)30014-8
Cabrita HA, Santos AL, Gobbi RG, Lima AL, Oliveira PR, Ejnisman L, Gurgel HM, Uip D, Camanho GL. AVASCULAR NECROSIS OF THE FEMORAL HEAD IN HIV-INFECTED PATIENTS: PRELIMINARY RESULTS FROM SURGICAL TREATMENT FOR CERAMIC-CERAMIC JOINT REPLACEMENT. Rev Bras Ortop. 2015 Nov 04;47(5):626-30. doi: 10.1016/S2255-4971(15)30014-8. eCollection 2012. PMID: 27047876; PMCID: PMC4799464.
Copy Download .nbib Format: NLM
Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin.

Hepatology research : the official journal of the Japan Society of Hepatology

Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Araki M, Ikegami T, Okubo T, Kondo C, Osada Y, Nakatsuka K, Chuganji Y, Matsuzaki Y, Iwakiri K, Aizawa Y.
PMID: 26289410
Hepatol Res. 2016 Mar;46(5):450-8. doi: 10.1111/hepr.12575. Epub 2015 Sep 17.

AIM: Protease inhibitors with pegylated interferon (PEG IFN)/ribavirin improve a sustained virological response (SVR) rate to approximately 90% in chronic hepatitis C genotype 1b patients with IL28B rs8099917 genotype TT, but yield only approximately 50% in those with the...

Cite
Atsukawa M, Tsubota A, Shimada N, et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatol Res. 2015;46(5):450-8doi: 10.1111/hepr.12575.
Atsukawa, M., Tsubota, A., Shimada, N., Yoshizawa, K., Abe, H., Asano, T., Ohkubo, Y., Araki, M., Ikegami, T., Okubo, T., Kondo, C., Osada, Y., Nakatsuka, K., Chuganji, Y., Matsuzaki, Y., Iwakiri, K., & Aizawa, Y. (2016). Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology research : the official journal of the Japan Society of Hepatology, 46(5), 450-8. https://doi.org/10.1111/hepr.12575
Atsukawa, Masanori, et al. "Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin." Hepatology research : the official journal of the Japan Society of Hepatology vol. 46,5 (2016): 450-8. doi: https://doi.org/10.1111/hepr.12575
Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Araki M, Ikegami T, Okubo T, Kondo C, Osada Y, Nakatsuka K, Chuganji Y, Matsuzaki Y, Iwakiri K, Aizawa Y. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatol Res. 2016 Mar;46(5):450-8. doi: 10.1111/hepr.12575. Epub 2015 Sep 17. PMID: 26289410.
Copy Download .nbib Format: NLM
Acquired von Willebrand Disease in Patients with Chronic Myeloproliferative Disorders.

Leukemia & lymphoma

Tatewaki W, Shibata A.
PMID: 27456408
Leuk Lymphoma. 1989;1(1):51-7. doi: 10.3109/10428198909042459.

In chronic myeloproliferative disorders(CMPD), thrombohaemorrhagic complications are relatively common, in association with thromocytosis. We studied the multimeric composition of plasma von Willebrand factor(vWf) in CMPD and investigated the possibilities of in vivo or in vitro proteolysis. The relative amount...

Cite
Tatewaki W, Shibata A. Acquired von Willebrand Disease in Patients with Chronic Myeloproliferative Disorders. Leuk Lymphoma. 1989;1(1):51-7doi: 10.3109/10428198909042459.
Tatewaki, W., & Shibata, A. (1989). Acquired von Willebrand Disease in Patients with Chronic Myeloproliferative Disorders. Leukemia & lymphoma, 1(1), 51-7. https://doi.org/10.3109/10428198909042459
Tatewaki, W, and Shibata, A. "Acquired von Willebrand Disease in Patients with Chronic Myeloproliferative Disorders." Leukemia & lymphoma vol. 1,1 (1989): 51-7. doi: https://doi.org/10.3109/10428198909042459
Tatewaki W, Shibata A. Acquired von Willebrand Disease in Patients with Chronic Myeloproliferative Disorders. Leuk Lymphoma. 1989;1(1):51-7. doi: 10.3109/10428198909042459. PMID: 27456408.
Copy Download .nbib Format: NLM
Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study.

Journal of clinical and translational hepatology

Flamm SL, Pockros PJ, Bengtsson L, Friedman M.
PMID: 26356545
J Clin Transl Hepatol. 2014 Jun;2(2):65-73. doi: 10.14218/JCTH.2014.00007. Epub 2014 Jun 15.

BACKGROUND AND AIMS: There is a paucity of information regarding similarities and differences between patients from the phase 3 studies of telaprevir and those receiving telaprevir in clinical practice.METHODS: This retrospective chart review evaluated baseline characteristics and follow-up safety...

Cite
Flamm SL, Pockros PJ, Bengtsson L, et al. Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. J Clin Transl Hepatol. 2014;2(2):65-73doi: 10.14218/JCTH.2014.00007.
Flamm, S. L., Pockros, P. J., Bengtsson, L., & Friedman, M. (2014). Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. Journal of clinical and translational hepatology, 2(2), 65-73. https://doi.org/10.14218/JCTH.2014.00007
Flamm, Steven L, et al. "Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study." Journal of clinical and translational hepatology vol. 2,2 (2014): 65-73. doi: https://doi.org/10.14218/JCTH.2014.00007
Flamm SL, Pockros PJ, Bengtsson L, Friedman M. Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. J Clin Transl Hepatol. 2014 Jun;2(2):65-73. doi: 10.14218/JCTH.2014.00007. Epub 2014 Jun 15. PMID: 26356545; PMCID: PMC4521261.
Copy Download .nbib Format: NLM
Changes in levels of enzyme inhibitors during soaking and cooking for pulses available in Canada.

Journal of food science and technology

Shi L, Mu K, Arntfield SD, Nickerson MT.
PMID: 28303052
J Food Sci Technol. 2017 Mar;54(4):1014-1022. doi: 10.1007/s13197-017-2519-6. Epub 2017 Feb 09.

The effects of processing (soaking and cooking) on enzyme inhibitors (α-amylase, trypsin and chymotrypsin inhibitors) in a range of pulses (4 peas, 9 lentils, 3 chickpeas, 2 faba beans and 4 beans) were investigated, using soybean as a control....

Cite
Shi L, Mu K, Arntfield SD, et al. Changes in levels of enzyme inhibitors during soaking and cooking for pulses available in Canada. J Food Sci Technol. 2017;54(4):1014-1022doi: 10.1007/s13197-017-2519-6.
Shi, L., Mu, K., Arntfield, S. D., & Nickerson, M. T. (2017). Changes in levels of enzyme inhibitors during soaking and cooking for pulses available in Canada. Journal of food science and technology, 54(4), 1014-1022. https://doi.org/10.1007/s13197-017-2519-6
Shi, Lan, et al. "Changes in levels of enzyme inhibitors during soaking and cooking for pulses available in Canada." Journal of food science and technology vol. 54,4 (2017): 1014-1022. doi: https://doi.org/10.1007/s13197-017-2519-6
Shi L, Mu K, Arntfield SD, Nickerson MT. Changes in levels of enzyme inhibitors during soaking and cooking for pulses available in Canada. J Food Sci Technol. 2017 Mar;54(4):1014-1022. doi: 10.1007/s13197-017-2519-6. Epub 2017 Feb 09. PMID: 28303052; PMCID: PMC5336459.
Copy Download .nbib Format: NLM
Transient Elastography for the Detection of Liver Damage in Patients with HIV.

Infectious diseases and therapy

Sagir A, Glaubach B, Sahin K, Graf D, Erhardt A, Oette M, Häussinger D.
PMID: 26143457
Infect Dis Ther. 2015 Sep;4(3):355-64. doi: 10.1007/s40121-015-0073-y. Epub 2015 Jul 05.

INTRODUCTION: Highly active antiretroviral therapy (HAART) is effective and well tolerated, but hepatotoxicity is relatively common. Different non-invasive methods are available for detecting liver fibrosis in patients with chronic liver disease.METHODS: Patients who were HIV positive and who had...

Cite
Sagir A, Glaubach B, Sahin K, et al. Transient Elastography for the Detection of Liver Damage in Patients with HIV. Infect Dis Ther. 2015;4(3):355-64doi: 10.1007/s40121-015-0073-y.
Sagir, A., Glaubach, B., Sahin, K., Graf, D., Erhardt, A., Oette, M., & Häussinger, D. (2015). Transient Elastography for the Detection of Liver Damage in Patients with HIV. Infectious diseases and therapy, 4(3), 355-64. https://doi.org/10.1007/s40121-015-0073-y
Sagir, Abdurrahman, et al. "Transient Elastography for the Detection of Liver Damage in Patients with HIV." Infectious diseases and therapy vol. 4,3 (2015): 355-64. doi: https://doi.org/10.1007/s40121-015-0073-y
Sagir A, Glaubach B, Sahin K, Graf D, Erhardt A, Oette M, Häussinger D. Transient Elastography for the Detection of Liver Damage in Patients with HIV. Infect Dis Ther. 2015 Sep;4(3):355-64. doi: 10.1007/s40121-015-0073-y. Epub 2015 Jul 05. PMID: 26143457; PMCID: PMC4575292.
Copy Download .nbib Format: NLM
Purification and Some Properties of a Protease from the Sarcocarp of Musk Melon Fruit.

Bioscience, biotechnology, and biochemistry

Kaneda M, Yonezawa H, Uchikoba T.
PMID: 27396886
Biosci Biotechnol Biochem. 1997 Jan;61(12):2100-2. doi: 10.1271/bbb.61.2100.

A protease has been purified from sarcocarp of musk melon, Cucumis melo ssp. melo var. reticulatus Naud. Earl's Favourite. The protease was mostly present in the placenta part of the fruit and next in the inside mesocarp. The molecular...

Cite
Kaneda M, Yonezawa H, Uchikoba T. Purification and Some Properties of a Protease from the Sarcocarp of Musk Melon Fruit. Biosci Biotechnol Biochem. 1997;61(12):2100-2doi: 10.1271/bbb.61.2100.
Kaneda, M., Yonezawa, H., & Uchikoba, T. (1997). Purification and Some Properties of a Protease from the Sarcocarp of Musk Melon Fruit. Bioscience, biotechnology, and biochemistry, 61(12), 2100-2. https://doi.org/10.1271/bbb.61.2100
Kaneda, M, et al. "Purification and Some Properties of a Protease from the Sarcocarp of Musk Melon Fruit." Bioscience, biotechnology, and biochemistry vol. 61,12 (1997): 2100-2. doi: https://doi.org/10.1271/bbb.61.2100
Kaneda M, Yonezawa H, Uchikoba T. Purification and Some Properties of a Protease from the Sarcocarp of Musk Melon Fruit. Biosci Biotechnol Biochem. 1997 Jan;61(12):2100-2. doi: 10.1271/bbb.61.2100. PMID: 27396886.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1337 entries